Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cryo Cell International (CCEL) EBITDA (2016 - 2026)

Cryo Cell International's EBITDA history spans 17 years, with the latest figure at $765134.0 for Q1 2026.

  • Quarterly results put EBITDA at $765134.0 for Q1 2026, down 27.54% from a year ago — trailing twelve months through Feb 2026 was $191517.0 (down 76.75% YoY), and the annual figure for FY2025 was $1.4 million, up 99.1%.
  • EBITDA for Q1 2026 was $765134.0 at Cryo Cell International, up from -$4.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.9 million in Q3 2025 to a low of -$16.2 million in Q4 2023.
  • The 5-year median for EBITDA is $1.1 million (2025), against an average of -$574744.6.
  • The sharpest move saw EBITDA tumbled 453.57% in 2023, then soared 81.37% in 2024.
  • Year by year, EBITDA stood at -$2.9 million in 2022, then tumbled by 453.57% to -$16.2 million in 2023, then soared by 81.37% to -$3.0 million in 2024, then crashed by 31.62% to -$4.0 million in 2025, then surged by 119.29% to $765134.0 in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at $765134.0, -$4.0 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.